文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛消化、代谢与肾脏急症

美国退伍军人COVID-19住院患者临床治疗与结局的种族差异

Variation in Clinical Treatment and Outcomes by Race Among US Veterans Hospitalized With COVID-19.
PubMed 文献 · JAMA Netw Open · 2022-10-03
一句话结论在130家退伍军人医疗中心,黑人COVID-19住院患者接受全身激素、瑞德西韦或免疫调节药物的可能性低于白人,但校正后院内死亡与30天再入院无差异。

这项回顾性队列研究纳入2020年3月1日至2022年2月28日在130家退伍军人医疗中心住院的43222例COVID-19退伍军人(黑人12135例[28.1%],白人31087例[71.9%],男性40717例[94.2%],中位年龄71岁[IQR 62-77])。控制治疗地点后,黑人患者入ICU的可能性与白人相当(39.6% vs 43.2%;中心内aOR 0.95;95%CI 0.88-1.02;P=.17)。黑人患者接受全身激素(中心内aOR 0.88;95%CI 0.80-0.96;P=.004)、瑞德西韦(中心内aOR 0.89;95%CI 0.83-0.95;P<.001)和免疫调节药物(中心内aOR 0.77;95%CI 0.67-0.87;P<.001)的可能性更低。校正人口学特征、慢性病、急性病严重度和COVID-19特异性治疗后,黑人种族与院内死亡(中心内aOR 0.98;95%CI 0.86-1.10;P=.71)或30天再入院(中心内aOR 0.95;95%CI 0.88-1.04;P=.28)无关联。

要点

  • 控制治疗地点后,黑人COVID-19住院患者入ICU比例与白人相当(39.6% vs 43.2%;中心内aOR 0.95;95%CI 0.88-1.02;P=.17)。
  • 黑人患者接受全身激素的可能性更低(中心内aOR 0.88;95%CI 0.80-0.96;P=.004;中心间aOR 0.67;95%CI 0.48-0.96;P=.03)。
  • 黑人患者接受瑞德西韦的可能性更低(中心内aOR 0.89;95%CI 0.83-0.95;P<.001;中心间aOR 0.68;95%CI 0.47-0.99;P=.02)。
  • 黑人患者接受免疫调节药物的可能性更低(中心内aOR 0.77;95%CI 0.67-0.87;P<.001)。
  • 校正人口学、慢性病、急性病严重度和COVID-19特异性治疗后,黑人种族与院内死亡(中心内aOR 0.98;95%CI 0.86-1.10;P=.71)及30天再入院(中心内aOR 0.95;95%CI 0.88-1.04;P=.28)无关联。

适用人群与场景

  • 2020年3月1日至2022年2月28日在130家退伍军人医疗中心住院的COVID-19退伍军人,随访60天至2022年5月1日。
  • 共43222例:黑人12135例(28.1%),白人31087例(71.9%),男性40717例(94.2%),中位年龄71岁(IQR 62-77)。

研究设计与关键结果

  • 回顾性队列研究,纳入130家退伍军人医疗中心43222例COVID-19住院退伍军人,比较黑人与白人患者的临床治疗和结局。
  • 控制治疗地点后,黑人患者入ICU与白人相当(4806例[39.6%] vs 13427例[43.2%];中心内aOR 0.95;95%CI 0.88-1.02;P=.17)。
  • 接受补充氧或无创/有创机械通气的患者中约三分之二接受全身激素,黑人接受激素可能性更低(中心内aOR 0.88;95%CI 0.80-0.96;P=.004;中心间aOR 0.67;95%CI 0.48-0.96;P=.03)。
  • 黑人接受瑞德西韦可能性更低(中心内aOR 0.89;95%CI 0.83-0.95;P<.001;中心间aOR 0.68;95%CI 0.47-0.99;P=.02)。
  • 黑人接受免疫调节药物可能性更低(中心内aOR 0.77;95%CI 0.67-0.87;P<.001)。
  • 校正人口学特征、慢性病、急性病严重度和COVID-19特异性治疗后,黑人种族与院内死亡(中心内aOR 0.98;95%CI 0.86-1.10;P=.71)及30天再入院(中心内aOR 0.95;95%CI 0.88-1.04;P=.28)无关联。

证据类型、等级与局限

  • 研究类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,这些发现提示黑人COVID-19住院退伍军人接受循证COVID-19治疗(包括全身激素、瑞德西韦和免疫调节药物)的可能性更低。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Patients from racially and ethnically minoritized populations, such as Black and Hispanic patients, may be less likely to receive evidence-based COVID-19 treatments than White patients, contributing to adverse clinical outcomes.

OBJECTIVE: To determine whether clinical treatments and outcomes among patients hospitalized with COVID-19 were associated with race.

DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study was conducted in 130 Department of Veterans Affairs Medical Centers (VAMCs) between March 1, 2020, and February 28, 2022, with a 60-day follow-up period until May 1, 2022. Participants included veterans hospitalized with COVID-19. Data were analyzed from May 6 to June 2, 2022.

EXPOSURES: Self-reported race.

MAIN OUTCOMES AND MEASURES: Clinical care processes (eg, intensive care unit [ICU] admission; organ support measures, including invasive and noninvasive mechanical ventilation; prone position therapy, and COVID-19-specific medical treatments) were quantified. Clinical outcomes of interest included in-hospital mortality, 60-day mortality, and 30-day readmissions. Outcomes were assessed with multivariable random effects logistic regression models to estimate the association of race with outcomes not attributable to known mediators, such as socioeconomic status and age, while adjusting for potential confounding between outcomes and mediators.

RESULTS: A total of 43 222 veterans (12 135 Black veterans [28.1%]; 31 087 White veterans [71.9%]; 40 717 [94.2%] men) with a median (IQR) age of 71 (62-77) years who were hospitalized with SARS-CoV-2 infection were included. Controlling for site of treatment, Black patients were equally likely to be admitted to the ICU (4806 Black patients [39.6%] vs 13 427 White patients [43.2%]; within-center adjusted odds ratio [aOR], 0.95; 95% CI, 0.88-1.02; P = .17). Two-thirds of patients treated with supplemental oxygen or noninvasive or invasive mechanical ventilation also received systemic steroids, but Black veterans were less likely to receive steroids (within-center aOR, 0.88; 95% CI, 0.80-0.96; P = .004; between-center aOR, 0.67; 95% CI, 0.48-0.96; P = .03). Similarly, Black patients were less likely to receive remdesivir (within-center aOR, 0.89; 95% CI, 0.83-0.95; P < .001; between-center aOR, 0.68; 95% CI, 0.47-0.99; P = .02) or treatment with immunomodulatory drugs (within-center aOR, 0.77; 95% CI, 0.67-0.87; P < .001). After adjusting for patient demographic characteristics, chronic health conditions, severity of acute illness, and receipt of COVID-19-specific treatments, there was no association of Black race with hospital mortality (within-center aOR, 0.98; 95% CI, 0.86-1.10; P = .71) or 30-day readmission (within-center aOR, 0.95; 95% CI, 0.88-1.04; P = .28).

CONCLUSIONS AND RELEVANCE: These findings suggest that Black veterans hospitalized with COVID-19 were less likely to be treated with evidence-based COVID-19 treatments, including systemic steroids, remdesivir, and immunomodulatory drugs.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Castro AD, Mayr FB, Talisa VB, et al. Variation in Clinical Treatment and Outcomes by Race Among US Veterans Hospitalized With COVID-19. JAMA Netw Open. 2022. PMID: 36282499. doi:10.1001/jamanetworkopen.2022.38507

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。